New Federal Contractors — February 24, 2026

Two small biz winners secure $209M obligated ($299M potential) for long-term infectious disease programs to 2030-2036, with 23-45% already outlayed.

$94M firm-fixed award to veteran-owned firm via open competition underscores competitive edge in disability exams despite ended period.

75% of total value ($359M) in ended contracts (2020 expiry) with low/no outlays ($10M/94M for VES; $0/192M for Qlarant).

$0-$10M outlays vs $192M-$94M obligations in three contracts signal funding delays or non-performance post-expiry.

Partial obligations ($111M vs $299M options) and cost-sharing in BARDA awards tie to agency continuity over 5-12 years.

$188M remaining outlays ($53M BARDA + $84M VES) plus $188M unexercised options in biotech R&D.

Small/veteran-owned firms winning 100% of open competitions signals entry for qualified players in HHS/VA biotech and med evals.

BARDA's 43% of total value ($209M) funds small biz anti-infectives/Marburg to 2036, reflecting sustained HHS biothreat focus.

VA/HHS awards to non-manufacturer service providers total $269M, with veteran/SDB edges in open comp.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M obligated with $188M options to 2036; highest growth potential in Marburg R&D.", "trigger"=>"Option exercise pushing to $299M"}

{"entity"=>"QLARANT Integrity Solutions", "reason"=>"$192M legacy with $0 outlay post-2020; flags follow-on risk/opportunity in CMS data services.", "trigger"=>"New CMS award or outlay activity"}

{"entity"=>"BARDA Budget Trends", "reason"=>"Funds 43% of period value; continuity critical for biotech signals.", "trigger"=>"FY2027 appropriations increase"}